ASC Therapeutics
We are dedicated to discovering, developing and delivering cures for intractable diseases
We are passionate about helping patients lead more hopeful, healthier and happier lives
Our Focus
ASC Therapeutics is "here to cure".
ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT™ and other gene editing technologies developed after 12 years of R&D at Applied Stem Cells, Inc.
The company’s therapeutic development pipeline includes several preclinical stage programs in gene and cell therapy progressing into clinical stage in 2021 focusing on several blood disorders.
We are devoted to find solutions for unmet medical needs and passionate about applying our new technologies to change people’s lives for the better. We hope to help patients lead healthier, more hopeful, and happier lives.
Vision
To provide cures to patients with intractable diseases through innovative technologies and therapeutics that are both groundbreaking and safe
Focus
ASC Therapeutics strives to discover, develop, and deliver gene and cell treatments to cure intractable and emerging diseases.
DNA
Our diverse team has decades of experience in cutting edge stem-cell and gene therapy research. Together we strive to be innovators to provide platforms to revolutionize the way diseases are treated.
Our Pipeline
Hemophilia A
Gene Therapy
Hemophilia A
Gene Editing
Hemophilia B
Gene Editing
B - Thalassemia
Gene Editing
GVHD
Cell Therapy / Phase 2B
Undisclosed
Gene editing, Gene / Cell Therapy
Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies.
Not only do we have excellent teams for our in-house discovery and pre-clinical programs, we also collaborate with world renowned research institutes to enhance the power of discovery. Utilizing our cumulative experience in stem cells and gene modification technology, we are beginning to tap into neurological and immunologic diseases, as well as cancer treatments.
0
Programs
Investors & Collaborators
Hermed Capital
Hermed Capital Fund (the “Fund”) is a private equity fund that will invest primarily in healthcare industry around the world.
Fosun International
Fosun International Limited is a technology-driven consumer group that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007.
Advantech Capital
Launched in January 2016 by Mr. Jianming Yu, Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.
Ping An Group
Ping An of China is devoted to becoming a world-leading personal financial services provider.
Stanford University
Stanford University, officially Leland Stanford Junior University, is a private research university in Stanford, California. Stanford is known for its academic achievements, wealth, close proximity to Silicon Valley, and selectivity; it ranks as one of the world's top universities.
Emory University
Emory University, a top-ranked private institution recognized internationally for its outstanding liberal arts colleges, graduate and professional schools, and one of the world's leading healthcare systems, is located on a beautiful campus in Atlanta, Georgia's historic Druid Hills neighborhood.
Shantou University
Shantou University, a key comprehensive university under the provincial Project 211 program in Guangdong, was founded in 1981 with the approval of the State Council. It is the only public university that receives funding from the Li Ka Shing Foundation.
Peking University Shenzhen Hospital
Peking University Shenzhen Hospital, opened in 1999, is a modern general hospital based in Shenzhen with an investment of RMB 4.5 billion. Under the cooperation of Shenzhen municipal government and Peking University, the hospital was absorbed into the management system of Peking University Hospital in the year 2001.
Simcere
Simcere Pharmaceutical Group is China's leading R&D-driven pharmaceutical company. It has been ranked amongst the top 100 pharmaceutical companies in China and in the top 10 of the most innovative pharmaceutical companies in China for several consecutive years. Simcere was the first Chinese biological and chemical pharmaceutical company to be listed on the New York Stock Exchange.
News
Phase 1/2 Trial Set to Test ASC618, Gene Therapy for Hemophilia A
The U.S. Food and Drug Administration (FDA) has approved ASC Therapeutics’...
Read MoreASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A
BusinessWire Transformational in-vivo AAV gene therapy for hemophilia A Efficiently...
Read More
ASC Therapeutics “Advanced Genome Editing, Gene & Cell Therapy Platforms in the US and China” won the first prize
ASC Therapeutics “Advanced Genome Editing, Gene & Cell Therapy Platforms...
Read More- Phase 1/2 Trial Set to Test ASC618, Gene Therapy for Hemophilia Aby Marta Figueiredo PhD on July 11, 2021 at 2:14 am
The U.S. Food and Drug Administration (FDA) has approved ASC Therapeutics’ request to open a clinical trial in the U.S. into the safety and early …
- ASC Therapeutics on LinkedIn: #genetherapy #celltherapy #biotechon July 8, 2021 at 3:56 am
ASC Therapeutics “Advanced Genome Editing, Gene & Cell Therapy Platforms in the US and China” won the first prize of the “2021 Fifth Forum For New …
- ASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia Aon July 8, 2021 at 2:54 am
MILPITAS, Calif.--(BUSINESS WIRE)--ASC Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ASC618 Second-Generation …
- The CRISPR breakthrough that can change the future of gene editingby Sy Mukherjee on July 2, 2021 at 12:49 pm
Happy Thursday, readers. While we continue to keep a close eye on the emergence of COVID variants, and what we may have to do about it, going into the …
- Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis | Intellia Therapeuticson June 27, 2021 at 4:15 am
• First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans• Interim readout in ongoing Phase 1 trial finds …